Download this White Paper
Cardiovascular diseases remain the leading cause of morbidity and mortality globally, prompting the need for safe and effective drugs and devices to treat these conditions. The emergence of CRISPR genome editing has opened up a new frontier in cardiovascular research, offering new possibilities for correcting genetic defects associated with cardiovascular diseases.
In this whitepaper, Medpace experts:
Offered Free by: Medpace
See All Resources from: Medpace